Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Bone Marrow Transplantation
|
December 13, 2025
Predictive values of baseline <sup>18</sup>F-FDG PET/CT for toxicities and outcomes in patients with relapsed or refractory multiple myeloma following BCMA CAR T-cell therapy
Pingnan Xiao, Xin Zhao, Linqin Wang, et al.
Nature
|
August 31, 2022
Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
Jiqin Zhang, Yongxian Hu, Jiaxuan Yang, et al.
Nature Medicine
|
September 24, 2025
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
Jingjing Feng, Dawei Huo, Ruimin Hong, et al.
Journal for Immunotherapy of Cancer
|
March 28, 2025
Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
Chunxiang Jin, Rongrong Chen, Shan Fu, et al.
Journal of Advanced Research
|
February 13, 2025
Sequential allogeneic HSCT after CAR-T therapy for relapsed/refractory acute lymphoblastic leukemia patients: A long-term follow-up result
Tingting Yang, Yetian Dong, Jimin Shi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
December 5, 2020
Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia
Xue Li, Xin Guo, Yuqing Zhu, et al.
JAMA Oncology
|
April 17, 2025
Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial
Mingming Zhang, Shan Fu, Jingjing Feng, et al.
Cell Research
|
September 23, 2022
Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study
Yongxian Hu, Yali Zhou, Mingming Zhang, et al.
Signal Transduction and Targeted Therapy
|
October 22, 2024
MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB
Xiujian Wang, Xiao Tao, Pengjie Chen, et al.
The New England Journal of Medicine
|
April 24, 2024
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis
Yongxian Hu, Mingming Zhang, Tingting Yang, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Bone Marrow Transplantation
|
December 13, 2025
Predictive values of baseline <sup>18</sup>F-FDG PET/CT for toxicities and outcomes in patients with relapsed or refractory multiple myeloma following BCMA CAR T-cell therapy
Pingnan Xiao, Xin Zhao, Linqin Wang, et al.
Nature
|
August 31, 2022
Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
Jiqin Zhang, Yongxian Hu, Jiaxuan Yang, et al.
Nature Medicine
|
September 24, 2025
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial
Jingjing Feng, Dawei Huo, Ruimin Hong, et al.
Journal for Immunotherapy of Cancer
|
March 28, 2025
Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
Chunxiang Jin, Rongrong Chen, Shan Fu, et al.
Journal of Advanced Research
|
February 13, 2025
Sequential allogeneic HSCT after CAR-T therapy for relapsed/refractory acute lymphoblastic leukemia patients: A long-term follow-up result
Tingting Yang, Yetian Dong, Jimin Shi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
December 5, 2020
Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia
Xue Li, Xin Guo, Yuqing Zhu, et al.
JAMA Oncology
|
April 17, 2025
Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial
Mingming Zhang, Shan Fu, Jingjing Feng, et al.
Cell Research
|
September 23, 2022
Genetically modified CD7-targeting allogeneic CAR-T cell therapy with enhanced efficacy for relapsed/refractory CD7-positive hematological malignancies: a phase I clinical study
Yongxian Hu, Yali Zhou, Mingming Zhang, et al.
Signal Transduction and Targeted Therapy
|
October 22, 2024
MEK inhibition prevents CAR-T cell exhaustion and differentiation via downregulation of c-Fos and JunB
Xiujian Wang, Xiao Tao, Pengjie Chen, et al.
The New England Journal of Medicine
|
April 24, 2024
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis
Yongxian Hu, Mingming Zhang, Tingting Yang, et al.
Page
of 6